innovent glp-1 China's says its works better than Novo's semaglutide in diabetes study Innovent Announces Mazdutide, First Dual

Retatrutide appears to have more average weight loss (24.2%) vs

Practical factorssuch as insurance coverage, approved indication (type 2 diabetes vs obesity), drug availability, previous side effects, and co-existing health conditionsusually matter more than subtle mechanistic differences when deciding which medication to use and how aggressively to dose it

Inside the GLP-1 Boom: What a Biotech Analyst and PhD/Nutritionist Thinks Mini-deep dive on the fastest growing healthcare opportunity from an investment and health perspective This is for: Science enthusiasts Pharma/biotech consultants, analysts Investors in the life science space Doctors, nutritionists, health coaches, fitness coaches People considering or already on weight loss medication Longevity enthusiasts I help you: Understand what weight loss medications are Get a list of the key obesity players in the pharma/biotech space Understand lifestyle strategies to get the best outcomes out of GLP1s Free Resources included: Obesity development landscape and launch timelines Weight loss data from key drugs in development Comment Health and I will share a US market model template to help you forecast weight loss drug sales yourself See inside for disclosure Intro to Weight Loss Medications (WLMs) Unless you are living under a rock, the words GLP1, Ozempic, Wegovy, Mounjaro, weight-loss medication must not be new to you

Another recent study using an even more specific method to detect (and rule out) GLP-1 receptors in tissues (a radioligand assay) did not confirm GLP-1 receptors in human thyroid tissue outside C cells (35)

Our medical team possesses deep knowledge and hands-on experience with advanced metabolic therapies like GLP-2

Accessed March 30, 2026